Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Does anyone have a extra idea for our retail IR list?
View:
Post by SouthernTierTom on Feb 04, 2021 10:44am

Does anyone have a extra idea for our retail IR list?

Nice words MM!


List of events and recent accomplishments;

* Full FDA approval for wholly-owned EAA diagnostic


* FULL not "EUA" FDA PMX ( blood filtration device ) approval for CV19 in US

* FULL Canada Health PMX approval for CV19

* FULL FDA approval for SAMI device

* FDA approval for DIMI device ( home dialysis pending on FDA home study detail )

* 6.5 MILLION CAD from Baxter for selling partnership arrangement - no strings / no surrender of  any company value.

* Pending FULL Canadien DIMI approval with detail to come iminently

* Data from 179 ( 194-16 CAD sites + 1 ) patients identified as usable data from phase 3 trial, to carry substantial weight in TIGRIS approval 

TIGRIS phase 3B/4 confirmatory trial that boasts a 2:1 in favor of our propsed PMX blood filtration device ( used safely and efficacously on over 200,000 patients in Japan and the EU )  * this was a 10 site trial expanded to 15 - Interim analysis H2 2021

* CV19 trial initially 2 sites expanded to 3 ( Conn , NY, Mass ) and expected to look at 75 patients - approaching one year mark - covid trial, expect covid didn't reduce recruitmrent

* Recent finance at 60 cents ( 11 new institutional players ) and 45 cent warrants to come due April/21 to add to adequate cash position

* Consolidation of 10 for 1 approved at last AGM ( by those able to vote )

* January 2021 hire of US invester realtions firm - see next point!

* Awaiting 2020 financials to make the move to a "senior US listing"  

* Options are due to be issued in days to weeks - new hire and BoD etc..

* NO other serious competition in our space.  NOBODY has the FDA advancement of us when it comes to the treatment of an endotoxemic septic shock patient....

* It looks quite interesting, I know I've been "offered up some alternatives, but I like this one for that "spectralative 3 to 5% of my portfoeleo.

* Always do your own homework and consult a pro in matters $50 USD or $100 CAD

Please feel free to add, perhaps a word or two from the long side?

Bon chance amigos!  Let's see what happens when word on this gem escapes the tiny world of Ithaca and specificallty the STIG ( Southern tier investment group ) and goes "viral" ( aka to 100 or so Yanks )

Best to all and let's be friends fellas..we are ALL here for each other to share ideas and learn about our investment..  .

Add to the list...we welcome ALL ; -)

Tommy A Tractor
Comment by Domino55 on Feb 04, 2021 11:28am
STT - I like your list. I would add the hiring of Dr. Kellum. This is an important advancement too. also, was their an announcement about hiring US investor relations?
Comment by mercedesman on Feb 04, 2021 11:35am
Agree !
Comment by Domino55 on Feb 04, 2021 2:26pm
Mm - when did they announce that they have an American IR partner. that was not in the recent shareholder presentations. I read the presentation and listened to both and there was no mention of this. if this is true the timing along with Dr. Kellum's hire and the intent to move up to a better US listing makes sense.
Comment by mercedesman on Feb 04, 2021 2:40pm
Agree. It was never formally announced that I am aware of. It was noted at the bottom of the follwoing NR https://stockhouse.com/news/press-releases/2021/01/06/spectral-medical-to-present-at-the-snn-network-canada-virtual-event-on-january Play where's Walden. Hint: Look towards the bottom. MM
Comment by Domino55 on Feb 04, 2021 2:47pm
It is at the bottom of the Dr. Kellum NR too. I think many people would miss this. Nobody reads that part of the news release. They must be planning a US IR launch to coincide with an upgraded listing. that would be huge
Comment by mercedesman on Feb 04, 2021 3:43pm
Hope so ! Long overdue.  Another clue is the fact that they plan to restate the FS for 2020 (and comparatives) presumabley to satisfy US listing requirements (GAAP?)   This was mentioned in the  shareholder update last Dec. "i's need to crossed and "t''s dotted. US plan is important.  Not child's play.
Comment by mercedesman on Feb 04, 2021 11:34am
Good summary, to which I might add: Upcoming Interim patient enrolment and another potentail Baxter milestone payment/cash infusion. Anticipated Interim patient enrollment (60%) Q2 or Q3 of 2021. Tigris is an Open Label, confirmatory Trial.  What happens if Dr's like what they see as far as results?  Also anticpated results from separate PMX/Covid Study. Although PMX may not be an ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities